Development
Vitro, S.A.B. de C.V.
VITOF
$0.15
-$0.51-77.27%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 2.45B | 2.44B | 2.40B | 2.35B | 2.27B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.45B | 2.44B | 2.40B | 2.35B | 2.27B |
| Cost of Revenue | 1.83B | 1.82B | 1.81B | 1.79B | 1.76B |
| Gross Profit | 616.38M | 619.69M | 588.62M | 557.96M | 508.37M |
| SG&A Expenses | 456.76M | 457.68M | 447.63M | 434.97M | 422.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 15.57M | 11.64M | 7.93M | 6.46M | -22.17M |
| Total Operating Expenses | 2.30B | 2.29B | 2.27B | 2.24B | 2.16B |
| Operating Income | 144.05M | 150.36M | 133.06M | 116.54M | 108.18M |
| Income Before Tax | 75.71M | 79.00M | 57.35M | 44.78M | -17.95M |
| Income Tax Expenses | -16.60M | 16.90M | 22.61M | 27.39M | 63.62M |
| Earnings from Continuing Operations | 92.31 | 62.10 | 34.74 | 17.38 | -81.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 402.00K | 460.00K | 419.00K | 480.00K | 133.00K |
| Net Income | 92.71M | 62.56M | 35.16M | 17.86M | -81.44M |
| EBIT | 144.05M | 150.36M | 133.06M | 116.54M | 108.18M |
| EBITDA | 266.95M | 270.43M | 252.53M | 235.11M | 229.32M |
| EPS Basic | 0.24 | 0.18 | 0.12 | 0.08 | -0.17 |
| Normalized Basic EPS | 0.22 | 0.22 | 0.19 | 0.17 | 0.07 |
| EPS Diluted | 0.24 | 0.18 | 0.12 | 0.08 | -0.17 |
| Normalized Diluted EPS | 0.22 | 0.22 | 0.19 | 0.17 | 0.07 |
| Average Basic Shares Outstanding | 1.50B | 1.55B | 1.53B | 1.55B | 1.89B |
| Average Diluted Shares Outstanding | 1.50B | 1.55B | 1.53B | 1.55B | 1.89B |
| Dividend Per Share | 0.06 | 0.06 | 0.06 | 0.06 | 0.02 |
| Payout Ratio | 43.15% | 63.94% | 28.44% | 55.98% | -0.12% |